10 October 2016
New Data on IntegraGen’s miR-31-3p Biomarker Featured in Presentation at 2016 ESMO Congress

Data presented concludes that miR-31-3p expression is predictive of anti-EGFR therapy effect on objective response, depth of response, and early tumor shrinkage in patients with metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial.